Antengene Announces Exclusive License Agreement With MPM BioImpact-Established K2 Therapeutics
Shanghai – June 21, 2026 – Cooley advised K2 Therapeutics, a biotech company established by MPM BioImpact, on its exclusive license agreement with Antengene Corporation Limited for ATG-106, a preclinical CDH6 x CD3 bispecific T cell engager (TCE) in development for solid tumors. Antengene also announced that it has entered into an option agreement to grant K2 Therapeutics the option to obtain exclusive global rights to develop and commercialize an undisclosed preclinical bispecific TCE candidate. Across both agreements, K2 Therapeutics’ rights extend globally, excluding Greater China.
Under the license agreement, Antengene is entitled to upfront and near-term considerations of approximately $20 million, consisting of cash and a minority equity stake in a newly established asset company and subsidiary of K2 Therapeutics, subject to the satisfaction of certain near-term conditions. Antengene is also eligible to receive developmental, regulatory and sales milestone payments of up to $960.5 million related to ATG-106, plus tiered royalties on future net sales.
Under the option agreement, upon exercise of the option, Antengene is entitled to receive upfront and near-term considerations of approximately $20 million, consisting of an option exercise fee, near-term payment and upfront payment, as well as a minority equity stake in the related asset company. Antengene would also be eligible to receive developmental, regulatory and sales milestone payments of up to $960.5 million related to the undisclosed TCE program, plus tiered royalties on future net sales.
Lawyers Yiming Liu, Bin Wang, Zack Gong and Ivy Wang led the Cooley transaction team advising K2 Therapeutics.
Cooley previously advised K2 Therapeutics on its exclusive license agreement with Adcoris Biopharma in April 2026.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related Contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.